 |
|
The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma
Tony Tsai, MD;
Joan M. O’Brien, MD
Arch Ophthalmol. 2008;126(3):413-415.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Despite the widespread application of highly successful treatments for achieving local tumor control, long-term survival rates for uveal melanoma have remained unchanged, because patients continue to succumb to metastatic disease.1 Data from long-term follow-up in patients with all types and sizes of uveal melanoma reveal that up to half will eventually die from metastases.2 Melanomas are notorious for early dissemination, and doubling time analysis suggests that most metastases occur years before the ocular tumor is diagnosed and treated.3 While this may be true, it is certainly not the case for all subsets of patients with uveal melanoma. Less than 20% of patients with medium-sized tumors in the Collaborative Ocular Melanoma Study died from histopathologically confirmed metastatic disease at 10 years of follow-up.4 Clinical and histologic risk factors for metastatic disease are well recognized. These include increased basal tumor dimensions, ciliary body involvement, the . . . [Full Text of this Article]
AUTHOR INFORMATION
Author Affiliations: Department of Ophthalmology, University of California at San Francisco.
RELATED ARTICLES
Cytogenetics in the Management of Uveal Melanoma: Are We There Yet?
Dennis M. Robertson
Arch Ophthalmol. 2008;126(3):409-410.
EXTRACT
| FULL TEXT
Role of Cytogenetics in Management of Uveal Melanoma
Jerry A. Shields, Carol L. Shields, Miguel Materin, Takami Sato, and Arupa Ganguly
Arch Ophthalmol. 2008;126(3):416-419.
EXTRACT
| FULL TEXT
|
